A comprehensively validated IVRT method reliably discriminates sameness and differences between several topical...

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery
• Analytical Chemistry

Background:

• In vitro release testing (IVRT) is increasingly accepted for biowaivers of topical products.
• The US FDA has not included IVRT in product-specific guidances for clotrimazole cream.
• Published literature often lacks supplemental selectivity in IVRT validation for topical biowaivers.

Purpose of the Study:

• To develop and validate a cost-effective IVRT method for 1% clotrimazole creams.
• To ensure the method aligns with recent FDA draft guidance for topical drug products.
• To assess the "sameness" of clotrimazole creams using IVRT.

Main Methods:

• Utilized an in vitro release testing (IVRT) system.
• Formulated creams with varying excipients to demonstrate supplemental selectivity.
• Included negative controls with altered clotrimazole concentrations (>30% or <40%) to assess discriminatory power.

Main Results:

• A simple, reliable, reproducible, and cost-effective IVRT method was developed and validated.
• The method demonstrated supplemental selectivity by assessing excipient impact on clotrimazole release.
• The validated IVRT method showed appropriate discriminatory power to identify product "sameness" or differences.

Conclusions:

• The validated IVRT method can accurately measure release from 1% clotrimazole creams.
• The method possesses the necessary supplemental selectivity and discriminatory power for biowaiver applications.
• This IVRT approach supports the assessment of topical "sameness" for clotrimazole creams, aligning with FDA draft guidance.